Activation of the Akt/nuclear factor-kappaB signaling axis in developing lung neoplasia.
Tichelaar
Jay W
JW
University of Cincinnati, Cincinnati, OH 45267-0056, USA. Jay.Tichelaar@UC.edu
Zhang
Yu
Y
LeRiche
Jean C
JC
Lam
Stephen
S
Anderson
Marshall W
MW
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D000518:Eflornithine / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000517:prevention & control; D016328:NF-kappa B / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt
D016588:Anticarcinogenic Agents; D016328:NF-kappa B; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D019819:Budesonide; D002392:Catechin; C045651:epigallocatechin gallate; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D000518:Eflornithine